FDA approves osimertinib

14 Nov 2015 1:47 PM | Lori Aubrey (Administrator)
FDA granted accelerated approval to osimertinib (TAGRISSO)  once daily tablets, AstraZeneca Pharmaceuticals LP, for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.  November 13, 2015.  More Information:  http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm472565.htm


Comments

Northern New England Clinical Oncology Society
P.O. Box 643
Sandown, NH 03873-0643
Telephone (603) 887-1948
info@nnecos.org

This website brought to you by:


Powered by Wild Apricot Membership Software